- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02994771
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema
Indicated for the Treatment of Secondary Lymphedema Associated with the Treatment of Breast Cancer.
Primary objective is to evaluate the safety and tolerability of a single dose of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, multi-center, uncontrolled first in human trial that uses a standard 3 + 3 dose escalation scheme. Lymfactin® will be administered as a single dose by ex vivo perinodal injection into the fat pad of a flap of tissue containing lymph nodes from the abdominal wall. This flap of tissue will then be surgically implanted into the axillary region of the affected arm. This treatment with Lymfactin® may be performed in conjunction with or without breast reconstruction surgery.
Up to two dose cohorts are planned to be included. Each dose of Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL:
- Cohort 1: Lymfactin® [1 x 10E10 vp]
- Cohort 2: Lymfactin® [1 x 10E11 vp]
Should the dose escalation go up to Cohort 2 with initiation of a subsequent Extension Cohort a total of 15 - 21 patients may be treated in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland
- Toeoeloe Hospital, Department of Plastic Surgery
-
Tampere, Finland
- Tampere University Hospital, Department of Plastic Surgery
-
Turku, Finland
- Turku University Hospital, Department of Plastic Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Female patients with secondary lymphedema associated with the treatment of breast cancer.
- Patient who understands and voluntarily signs informed consent prior to any screening procedure.
- 18 - 70 years of age.
- BMI between 18 and 32 inclusive.
Female patients with secondary lymphedema in the arm associated with breast cancer who:
- Have undergone sentinel lymph node biopsies and/or lymph node resection in the axilla on the affected side of their breast cancer with initial N1 staging and lymph node metastasis in ≤ three lymph nodes.
- Require garment use as a compression treatment for the lymphedema in the affected arm.
- Have the volume of the affected arm at least 10% greater than the unaffected arm following 7 days after removal of the compression garments.
- Have the presence of pitting edema in the affected arm without compression garments.
- No evidence of recurrent or active breast cancer at least 2 years and no more than 5 years after breast cancer surgery and/or the end of chemotherapy and/or radiotherapy (excluding endocrine and/or aromatase inhibitor treatment). PET CT scan of the chest and the abdomen within 45 days of treatment with Lymfactin® without signs of active breast cancer or any other malignancy.
Patient with the following laboratory values:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the institutional upper limit of normal (ULN)
- Bilirubin ≤ 1.5 mg/dL
- PT and PTT ≤ 1.5 times the ULN
- Serum creatinine ≤ 2 mg/dL
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10 g/dL
- Willingness to comply with scheduled visits, laboratory assessments, and other study-related procedures due to the regulatory requirements related to gene based therapies.
- Non-smoker or willing to stop smoking or using nicotine-containing products for at least 4 weeks prior to entry to study.
Negative urine pregnancy test (only patients with childbearing potential) at screening and use of adequate contraceptive measures from screening until 6 months after the study treatment administration:
- A patient with childbearing potential should be using a reliable contraception method: intrauterine device (hormonal or non-hormonal); oral combination pill or hormonal contraception patch; or two of the following: intra-vaginal hormonal ring, oral contraceptive containing progestin only, spermicidal foam, condom, sterilization of male sexual partner (surgical vasectomy).
- A patient with no current heterosexual relationship may be included according to the judgement of the Investigator.
- If the patient is surgically sterile or whose menopause occurred 2 years previously at the minimum, no contraception is required nor pregnancy test.
Exclusion criteria:
- A patient who had an N2/N3 or a T4 stage breast cancer or an inflammatory breast cancer at the time of the original diagnosis.
- A patient with evidence (clinical, laboratory, or imaging) or history of a neoplasm other than breast cancer (except basal cell carcinoma or cervical in situ carcinoma).
- A patient known to be pregnant, lactating or having a positive or indeterminate pregnancy test.
- Treatment with COX-2 inhibitors should be interrupted from one week prior until 2 weeks post surgery and treatment with Lymfactin®.
- Previous treatment with, or participation in, trial of a gene therapy product.
- Current participation or participation in the preceding two months, in any clinical study apart from a noninterventional study.
- Current treatment with immunosuppressive drugs.
- Current or history of drug, including nicotinecontaining products, or alcohol abuse.
- Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
- Allergy to any ingredients of the Lymfactin® solution for injection (glycerol, N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid (HEPES), sodium hydroxide).
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, that would affect the patient's ability to follow study-related procedures, or that may interfere with the interpretation of study results and, in the Investigator's opinion, would make the patient inappropriate for entry into this study.
- Doubtful availability, in the opinion of the Investigator, to complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lymfactin® [1 x 10E10 vp]
Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
|
Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Other Names:
|
Active Comparator: Lymfactin® [1 x 10E11 vp]
Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
|
Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by number of patients with treatment related adverse events and serious adverse events as assessed by CTCAE v4.0
Time Frame: baseline to 1 year, yearly up to 5 years
|
Adverse events and serious adverse events assessed by CTCAE v4.0 to evaluate the safety profile after administration of Lymfactin
|
baseline to 1 year, yearly up to 5 years
|
CT scan of chest and abdomen
Time Frame: baseline, yearly up to 5 years
|
Changes in the CT scan of chest and abdomen in order to detect malignancies
|
baseline, yearly up to 5 years
|
Biodistribution of Lymfactin in blood
Time Frame: 90 days
|
Changes in Lymfactin genome copy number in blood
|
90 days
|
Formation of anti-Lymfactin antibodies
Time Frame: 6 months
|
Changes in the anti-Lymfactin antibody titer in blood
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of the volume of the arms
Time Frame: baseline, 6, 12, 24 and 36 months
|
Changes in the volume of the affected arm and comparison to the unaffected arm
|
baseline, 6, 12, 24 and 36 months
|
Measurement of the lymphatic flow of the affected arm by quantitative lymphoscintigraphy (99Tc-nanocolloid clearance rate with calculation of transport index)
Time Frame: baseline, 12, 24 and 36 months
|
Assessment of the changes in the lymphatic flow
|
baseline, 12, 24 and 36 months
|
Questionnaire according to the Lymphedema Quality of Life Inventory (LQOLI)
Time Frame: baseline, 6, 12, 24 and 36 months
|
Assessment of changes in the quality of life using Lymphedema Quality of Life Inventory (LQOLI) in which patients assess how their lymphedema is affecting the activities of daily living.
LQOLI consists of three dimensions: Physical, psychosocial and practical, which are reported separately as the mean score of each dimension.
Each dimension of the LQOLI is scored from 0 to 3, where score 0 means "no impact", 1 means "a little bit impact", 2 means "somewhat impact", and 3 means "significant impact" on the quality of life of the patient, the smaller score thus being the better.
|
baseline, 6, 12, 24 and 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne Saarikko, MD, PhD, HUCH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL12001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Lymphedema
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
ThuasneUniversity Hospital, Tours; Delta ConsultantsCompletedLymphedema, Secondary | Lymphedema of Leg | Lymphedema Congenital | Lymphedema PrimaryFrance
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Inland Norway University of Applied SciencesMontebellosenteret, Mesnali, NorwayCompletedLymphedema, SecondaryNorway
-
University Hospital, MontpellierCompletedPrimary Lymphedema Secondary LymphedemaFrance
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
Our Lady of the Lake HospitalCompletedSecondary Lymphedema | Lymphedema of FaceUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Isabel Forner-Cordero, MD, PhD.CompletedSecondary Lymphedema | Primary LymphedemaSpain
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingLymphedema, Secondary | Lymphedema of Leg | Lymphedema Related FibrosisUnited States
Clinical Trials on Lymfactin® [1 x 10E10 vp]
-
Herantis Pharma Plc.Active, not recruitingSecondary LymphedemaFinland, Sweden
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome TrustCompletedEbola | Ebola ZaireUnited Kingdom
-
PATHCompleted
-
Crucell Holland BVThe PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...Completed
-
Ferring PharmaceuticalsCompletedNeed for Bowel PreparationUnited States
-
University of OxfordBiopharma (Orofino Pharmaceuticals Group)Not yet recruiting
-
Becton, Dickinson and CompanyCompletedContrast Enhanced Computed TomographyUnited States
-
Brien Holden VisionCompleted
-
Brien Holden VisionCompletedRefractive Error | PresbyopiaAustralia
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); Genzyme, a Sanofi CompanyCompletedAcute Myeloid LeukemiaUnited States, Singapore